Humacyte: Revenue Ramp From Symvess Incoming

2025-06-11 09:05:31 ET

Humacyte ( HUMA ), the Durham, North Carolina-based biotech company founded in 2004, develops and manufacturers bioengineered human blood vessels and tissues for the treatment (repair and replacement) of various vascular conditions. They have one product in the market, Symvess, which I’ll discuss in more detail below. The company has seen its share price fall significantly since 2021, when it completed its reverse merged via SPAC Alpha Healthcare Acquisition Corp. It remains a high risk but potentially high reward stock....

Read the full article on Seeking Alpha

For further details see: